Abstract 2868
Background
The aims of this study were to understand the prevalence of chemotherapy (chemo) use and its associated impact on survival in patients (pts) with either bone- and soft-tissue sarcomas (STS) through a large real-world population dataset.
Methods
A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority (HA) between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window. Drug dispensing records of chemotherapy drugs (chemo) from the HA as categorized by the British National Formulary 8.x were extracted and correlated with all-cause and cancer specific mortality.
Results
Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS n = 2576, both n = 121. 32.8% of pts (n = 1100) had chemo prescribed during the study period. The proportional use of chemo decreased with advancing age (<18y: 70.9%; 18-<40y: 42.2%; 40-65y: 36.1%, 65-80y: 19.7%;.>/=80y: 8.1%). Anthracyclines (AN) were the most commonly used class of chemo (19.8%), followed by alkylating drugs (17.3%), antimetabolites (11.9%) and vinca alkaloids & etoposide (8.7%). Comparing with pts who have not received chemo within the study period, the risk for death was higher in pts who have received AN either as first chemo (HR 1.51, 95%CI1.25-1.83; p < 0.001) or later lines of therapy (HR 1.55; 95%CI1.10-2.17; p = 0.002), and in pts who have had chemo but never received AN (HR 1.51; 95%CI1.27-1.80; p < 0.001). AN use resulted in significant reduction in mortality over non-AN chemo use if used within 3months of index diagnosis. This significance was not apparent in pts who started chemo >3months post diagnosis (log-rank p < 0.01 and p = 0.14 respectively). The impact of chemo on mortality reduction appeared greater in pts with bone- vs. STS.
Conclusions
This is one of the largest assembled population-based real-world sarcoma cohort. Chemo use and choice of chemo has implications on survival. The positive effect on survival was especially prominent in pts with bone sarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract